why is there a shortage of semaglutide RACGP Compounded Semaglutide & Tirzepatide 2025:

That matters for strength, function, independence, and long-term health

Multi+ is a dietary supplement, not a GLP-1 medication, and it does not replace a varied diet, adequate protein, fiber, fluids, or individualized medical care

Adjustable fit and reusable

GLP-1 medications do more than weight loss

Why This Matters for Clinical & Commercial Strategy: The collaboration signals: Increasing competition in the GLP-1 segment Strategic brand differentiation in high-demand therapies Strong focus on access expansion beyond metro & premium clinics Growing India focus in metabolic & obesity management For professionals in Clinical Research, Market Access, and Business Development, this is a clear indicator of how partnerships are shaping the next phase of diabetes and obesity care in India